These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8843625)

  • 1. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model.
    Devi SJ
    Vaccine; 1996 Jun; 14(9):841-4. PubMed ID: 8843625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
    Beenhouwer DO; May RJ; Valadon P; Scharff MD
    J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
    Devi SJ; Schneerson R; Egan W; Ulrich TJ; Bryla D; Robbins JB; Bennett JE
    Infect Immun; 1991 Oct; 59(10):3700-7. PubMed ID: 1716613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
    May RJ; Beenhouwer DO; Scharff MD
    J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.
    Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA
    Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R; Lees A; Pirofski L
    J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
    Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies.
    Zhong Z; Pirofski LA
    Infect Immun; 1996 Sep; 64(9):3446-50. PubMed ID: 8751883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
    Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
    Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
    Zhang H; Zhong Z; Pirofski LA
    Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW; Datta K; Pirofski LA
    Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.
    Datta K; Lees A; Pirofski LA
    Clin Vaccine Immunol; 2008 Aug; 15(8):1176-87. PubMed ID: 18524882
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Colombo AC; Rella A; Normile T; Joffe LS; Tavares PM; de S Araújo GR; Frases S; Orner EP; Farnoud AM; Fries BC; Sheridan B; Nimrichter L; Rodrigues ML; Del Poeta M
    mBio; 2019 Apr; 10(2):. PubMed ID: 30940711
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.
    Mukherjee J; Casadevall A; Scharff MD
    J Exp Med; 1993 Apr; 177(4):1105-16. PubMed ID: 8459205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
    Pirofski LA
    Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures.
    Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A
    Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
    Deshaw M; Pirofski LA
    Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
    Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR
    J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semisynthetic Glycoconjugate Vaccine Candidates against
    Crawford CJ; Liporagi-Lopes L; Coelho C; Santos Junior SR; Moraes Nicola A; Wear MP; Vij R; Oscarson S; Casadevall A
    ACS Infect Dis; 2024 Jun; 10(6):2089-2100. PubMed ID: 38819951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.